Last reviewed: July 27, 2026
Human evidence for fisetin is still early, fragmented, and much smaller than the online hype suggests. As of this review, the public record shows a growing pipeline of registered human studies across healthy aging, frailty, osteoarthritis, COVID-19, carpal tunnel syndrome, and breast-cancer survivorship. But only a small number of human fisetin studies have produced peer-reviewed outcome papers so far, and the published signal is mixed rather than definitive. One completed randomized crossover study in Gulf War Illness did not find fisetin superior to placebo, while a small 2024 pilot study in healthy adults used a repeating fisetin schedule and reported mixed results, with the authors explicitly cautioning against recommending fisetin as an anti-aging agent until larger studies are done. ClinicalTrials.gov: NCT07195318 ClinicalTrials.gov: NCT06431932 PubMed PMID 33802381 PubMed PMID 39269340
If you want the broader context beyond the trial tracker itself, the best companion pages are the fisetin dosage research summary, the broader fisetin research and safety overview, and the fisetin senolytic overview.
Current state of human evidence in one paragraph
The current human evidence base is best described as promising but preliminary. ClinicalTrials.gov shows multiple ongoing or recently active fisetin studies using very different schedules: 100 mg daily for 7 weeks, 100 mg daily for 90 days, 20 mg/kg/day for 2 consecutive days, 2 mg/kg/day in separated 3-day blocks, and repeated pulse schedules in oncology and frailty settings. That variety is scientifically interesting, but it also means there is no settled human fisetin protocol, no universally accepted "senolytic schedule," and no basis for treating registry entries as proof of efficacy. ClinicalTrials.gov: NCT07195318 ClinicalTrials.gov: NCT06133634 ClinicalTrials.gov: NCT06431932 ClinicalTrials.gov: NCT03430037
How to read this tracker
This tracker focuses on registered fisetin clinical trials and human studies, using ClinicalTrials.gov and peer-reviewed publications as the principal sources. "Results status" below means one of four things: a peer-reviewed publication exists, registry results are posted, no results were identified, or the record is still ongoing. Where a field was not clearly visible in the public record retrieved for this review, it is marked that way rather than guessed.
Completed fisetin clinical trials with published results
| Registry | Study title | Condition / population | Sample size | Dose | Schedule | Study design | Primary endpoint | Recruitment status | Results status | Publication link |
|---|---|---|---|---|---|---|---|---|---|---|
| NCT02909686 | Effects of Botanical Microglia Modulators in Gulf War Illness | Male veterans with Gulf War Illness | 21 completed in published fisetin analysis | Fisetin 200–800 mg/day | 1 month lower-dose fisetin period and 1 month higher-dose fisetin period within placebo-controlled crossover screening design | Placebo-controlled, pseudo-randomized crossover trial | Symptom severity of Gulf War Illness | Completed | Peer-reviewed publication found; registry results not identified in retrieved materials | [PMID 33802381](https://pubmed.ncbi.nlm.nih.gov/33802381/) |
The key point here is not that fisetin has "clinical proof," but that one of the most concrete completed randomized human datasets is actually negative: the published Gulf War Illness study reported that fisetin did not reduce symptom severity more than placebo. That makes it one of the most important reality-check studies in the field. PubMed PMID 33802381
Completed trials with registry results but no peer-reviewed publication identified
| Registry | Study title | Condition / population | Sample size | Dose | Schedule | Study design | Primary endpoint | Recruitment status | Results status | Publication link |
|---|---|---|---|---|---|---|---|---|---|---|
| NCT04771611 | COVFIS-HOME: A Phase 2 Placebo-Controlled Pilot Study in COVID-19 of Fisetin to Alleviate Dysfunction and Decrease Complications in At-Risk Outpatients | At-risk adult outpatients with COVID-19 | 55 actual | ~20 mg/kg/day oral | Days 0, 1, 8, and 9 | Phase 2 randomized, double-blind, placebo-controlled parallel trial | WHO ordinal scale score at 60 days | Completed | Registry results posted on ClinicalTrials.gov; no peer-reviewed paper identified at last review | — |
| NCT05416515 | Phase 2 Clinical Trial of FIsetin to Treat CArpal Tunnel Syndrome (FITCATS) | Adults with mild to moderate carpal tunnel syndrome | 40 actual | 100 mg capsules | 2 consecutive days, then another 2 consecutive days one month later | Phase 2 open-label single-group study | Change in Boston Carpal Tunnel Syndrome Questionnaire score | Completed | Registry results posted on ClinicalTrials.gov; no peer-reviewed paper identified at last review | — |
These trials matter because they expand the human evidence base beyond the older Gulf War Illness study, but they should still be read cautiously until peer-reviewed analyses are available. Registry-posted results are valuable, but they are not automatically the same thing as a fully interpreted journal publication. ClinicalTrials.gov: NCT04771611 ClinicalTrials.gov: NCT05416515
Recruiting or active fisetin trials
| Registry | Study title | Condition / population | Sample size | Dose | Schedule | Study design | Primary endpoint | Recruitment status | Results status | Publication link |
|---|---|---|---|---|---|---|---|---|---|---|
| NCT07195318 | Low-dose Fisetin Supplementation for Healthy Aging | Relatively healthy middle-aged and older adults | 120 planned | 100 mg | Daily for 7 weeks | Triple-blind randomized placebo-controlled trial | Safety and anti-inflammatory / healthy-aging measures in registry summary | Recruiting at last public listing reviewed | Ongoing; no results posted identified | — |
| NCT06431932 | Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity | Healthy volunteers plus older adults with multimorbidity | Healthy-volunteer sub-study n=20 visible in retrieved record; total overall enrollment not clearly visible | 20 mg/kg/day | 2 consecutive days with follow-up up to ~3 months | Pilot PK/safety-focused clinical study with healthy-volunteer and older-patient components | Pharmacokinetic profile / metabolites and safety-adverse events | Recruiting at last public listing reviewed | Ongoing; no results posted identified | — |
| NCT06133634 | Clinical Translation of Senolytic Therapy With Fisetin to Improve Vascular Function in Older Adults | Adults ≥65 with aging-related vascular dysfunction features | 70 estimated | 2 mg/kg/day | Two 3-day dosing periods separated by 2 weeks | Phase 1/2 randomized, triple-blind, placebo-controlled parallel trial | Change from baseline in endothelial function at 1 month (brachial artery flow-mediated dilation) | Active, not recruiting at last public listing reviewed | Ongoing; no results posted identified | — |
| NCT05595499 | Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors | Chemotherapy-treated postmenopausal stage I–III breast cancer survivors | Not clearly visible in retrieved registry snippet | Not clearly quantified in retrieved abstract snippet | Oral fisetin on days 1–3 every 14 days for up to 8 weeks | Phase 2 randomized placebo-controlled trial | 6-minute walk distance | Recruiting in current public cancer-trial listing reviewed | Ongoing; no outcome paper yet | [PMID 41835341](https://pubmed.ncbi.nlm.nih.gov/41835341/) (design / study paper) |
| NCT06113016 | Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors | Chemotherapy-treated postmenopausal breast cancer survivors | Target enrollment not clearly visible on retrieved registry page excerpt | Not clearly quantified in retrieved snippet | Fisetin on days 1–3 every 14 days for 8 cycles in fisetin-containing arms, with or without exercise | Phase 2 randomized 4-arm study | 6-minute walk distance | Recruiting in current public cancer-trial listing reviewed | Ongoing; no outcome paper identified | — |
| NCT04815902 | Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis | Osteoarthritis / bone-marrow stem-cell adjunct setting | Not clearly visible in retrieved record | Not clearly visible in retrieved record | Not clearly visible in retrieved record | Prospective randomized, double-blind, active-control clinical trial | Not clearly visible in retrieved public excerpt | Public listing suggests ongoing / active record; verify on registry before updating | No published results identified | — |
*For a living tracker, recruitment status should be rechecked on the registry before each update cycle.
These are the trials to watch because they will likely shape the next phase of fisetin human evidence. Just as importantly, they show how varied the field still is: low-dose daily supplementation, short weight-based pulses, every-2-week oncology cycles, and biomarker-focused PK studies are all being tested side by side. That is not what a mature evidence base looks like; it is what an emerging one looks like. ClinicalTrials.gov: NCT07195318 ClinicalTrials.gov: NCT06133634 ClinicalTrials.gov: NCT06431932 ClinicalTrials.gov: NCT05595499 ClinicalTrials.gov: NCT06113016
Withdrawn or terminated trials
| Registry | Study title | Condition / population | Sample size | Dose | Schedule | Study design | Primary endpoint | Recruitment status | Results status | Publication link |
|---|---|---|---|---|---|---|---|---|---|---|
| NCT03675724 | AFFIRM-LITE: A Phase 2 Randomized, Placebo-Controlled Study of Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Adults | Older adults ≥70 | 40 estimated | 20 mg/kg/day | Orally for 2 consecutive days | Phase 2 randomized, double-blind, parallel trial | Percent decrease in blood inflammation markers at 7 days | Terminated | No peer-reviewed publication identified | — |
A terminated trial does not prove a compound failed, but it does matter for evidence quality. It means the evidence pipeline is thinner than a casual search result might suggest. ClinicalTrials.gov: NCT03675724
Registered trials with unclear or not recently verified status in the retrieved public record
| Registry | Study title | Condition / population | Sample size | Dose | Schedule | Study design | Primary endpoint | Recruitment status | Results status | Publication link |
|---|---|---|---|---|---|---|---|---|---|---|
| NCT03430037 | AFFIRM: A Phase 2 Randomized, Placebo-Controlled Study of Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women | Postmenopausal women ≥70 with frailty-related endpoints | 40 estimated | 20 mg/kg/day | 2 consecutive days, for 2 consecutive months | Phase 2 randomized, double-blind parallel trial | Improved 6-minute walk / gait speed at 1 month | Registry excerpt retrieved as unknown / needs manual status re-check | No publication identified | — |
| NCT04210986 | Senolytic Drugs Attenuate Osteoarthritis-Related Articular Cartilage Degeneration: A Clinical Trial | Symptomatic knee osteoarthritis | Not clearly visible in retrieved record | Not clearly visible in retrieved public snippet | Not clearly visible in retrieved public snippet | Prospective randomized controlled trial | Adverse events per retrieved protocol snippet | Current status not clearly extractable from retrieved record | No results/publication identified | — |
| NCT04770064 | Targeting Senescence to Reduce Osteoarthritis Pain and cartilagE Breakdown (ROPE) | Mild to moderate knee osteoarthritis | 60 planned; retrieved record also showed actual enrollment 0 | ~20 mg/kg short-duration arm and 100 mg daily arm | 2-day pulse + 28-day washout + 2 days vs 100 mg daily for 90 days | Phase 1/2 double-blind randomized comparison of 2 fisetin regimens vs placebo | Pain / function comparison in registry summary; exact primary endpoint not fully visible in retrieved excerpt | Current status not clearly extractable from retrieved record | No results/publication identified | — |
This "unclear status" bucket is not a flaw in the concept of the tracker; it is actually useful editorially. It signals which records need manual re-checking during future updates, rather than letting stale status labels remain unchallenged.
Why trial registration does not prove effectiveness
A registry entry is a promise of a study plan, not proof that the intervention works. Registration improves transparency: it tells you what investigators intended to study, in whom, using what design. But it does not tell you the intervention succeeded, that the endpoints were met, that the data were clinically meaningful, or that the results were ever fully published. ClinicalTrials.gov: NCT07195318 ClinicalTrials.gov: NCT03675724
Fisetin is a good example of why this distinction matters. The registry is busy: ongoing trials, dose comparisons, pulse schedules, oncology adjunct studies, vascular-function studies. But one of the clearest completed randomized human studies, the Gulf War Illness crossover trial, found that fisetin did not improve symptom severity over placebo. Meanwhile, some registered trials have no peer-reviewed outcome paper yet, some have only registry results, and some have unclear or terminated status. That is a real research pipeline, but it is not the same as clinical proof. PubMed PMID 33802381 ClinicalTrials.gov: NCT04771611 ClinicalTrials.gov: NCT05416515
Strongest published human evidence so far
The strongest peer-reviewed fisetin evidence in humans is still limited.
The most concrete randomized human outcome paper is the Gulf War Illness study linked to NCT02909686. It was placebo-controlled and crossover in design, and fisetin did not reduce symptom severity more than placebo. That does not close the book on fisetin, because the population and endpoints were specific, but it does show that the strongest published randomized evidence is not clearly positive. PubMed PMID 33802381
A second important human publication is the 2024 pilot study in healthy adults over age 50. It used 500 mg daily for one week per month for six months. The sample was very small, results were mixed, and the abstract explicitly concluded that taking fisetin as an anti-aging agent was not recommended until more extensive studies are done. This is one of the clearest examples of why small early human studies should not be turned into marketing claims or dosing rules. PubMed PMID 39269340
A third category of evidence is registry-posted results without a peer-reviewed paper, such as COVFIS-HOME and FITCATS. Those records matter and should be watched, but in evidence-ranking terms they sit below a completed peer-reviewed randomized outcome paper. ClinicalTrials.gov: NCT04771611 ClinicalTrials.gov: NCT05416515
Major unanswered questions
The main unanswered questions are not small ones. Researchers still do not know whether daily low-dose fisetin or intermittent pulse dosing is more informative in humans, whether any regimen meaningfully improves hard clinical outcomes, which populations are most appropriate for study, and whether biomarker shifts translate into benefits people can actually feel or functionally measure. ClinicalTrials.gov: NCT07195318 ClinicalTrials.gov: NCT06133634 ClinicalTrials.gov: NCT04770064
Formulation is another major unknown. Trials vary between fixed milligram dosing and weight-based dosing, and the healthy-aging registry entry explicitly notes that supplement quality and active content can vary in the marketplace. That means a trial result, even if positive, would still need interpretation before being generalized to consumer products. ClinicalTrials.gov: NCT07195318
Long-term safety is also not established. The field has more ongoing trials than mature long-duration published datasets, which means the safety conversation remains exploratory rather than settled. PubMed PMID 39269340 ClinicalTrials.gov: NCT07195318
Why this tracker is updateable
This page can be updated on a regular schedule because the core fields are stable: registry ID, study title, condition, enrollment, dose, schedule, design, endpoint, recruitment status, results status, publication link. The most important recurring maintenance tasks are checking for status changes, new registry results, and new PubMed publications linked to existing NCT numbers.
FAQ
What are fisetin clinical trials?
They are registered or published human studies testing fisetin in specific populations, such as older adults, people with osteoarthritis, cancer survivors, COVID-19 outpatients, or people with carpal tunnel syndrome.
How many fisetin human trials are there?
As of this review, public registry searches identified a growing set of fisetin-related ClinicalTrials.gov records across multiple conditions, but the number of peer-reviewed completed outcome papers is still small.
Do fisetin clinical trial results prove fisetin works?
No. A trial must be completed, analyzed, and ideally peer-reviewed before it meaningfully informs efficacy. Registration alone does not prove effectiveness.
What is the most important completed fisetin trial?
The Gulf War Illness crossover study is arguably the most important completed peer-reviewed randomized human fisetin trial currently available, and it did not show benefit over placebo. PubMed PMID 33802381
Are there ongoing fisetin trials?
Yes. Ongoing or recently active records include healthy-aging, vascular-function, multimorbidity, osteoarthritis, and breast-cancer-survivorship studies. ClinicalTrials.gov: NCT07195318 ClinicalTrials.gov: NCT06133634 ClinicalTrials.gov: NCT06431932
Are there fisetin senolytic trials?
Yes, several fisetin studies explicitly frame the intervention around senescence or senolytic hypotheses, especially in aging, frailty, vascular, osteoarthritis, and oncology contexts. ClinicalTrials.gov: NCT06133634 ClinicalTrials.gov: NCT03430037 ClinicalTrials.gov: NCT05595499
What is the difference between registry results and a publication?
Registry results are study outcomes posted to ClinicalTrials.gov. A publication is a peer-reviewed journal article. The latter usually provides fuller interpretation and external review.
Have any fisetin studies in humans shown clear benefit?
Not clearly enough to establish a consensus. Some signals remain under investigation, but the published human literature is still sparse and mixed.
Is there a standard fisetin clinical trial dose?
No. Human studies use widely different regimens, including 100 mg daily, 500 mg repeating monthly blocks, and weight-based schedules such as 20 mg/kg/day or 2 mg/kg/day. ClinicalTrials.gov: NCT07195318 ClinicalTrials.gov: NCT06133634 ClinicalTrials.gov: NCT06431932 PubMed PMID 39269340
Why are some fisetin trials missing publications?
Because not every completed trial is quickly or fully published. Some studies post registry results first; some publish later; some never produce a peer-reviewed paper.
Do supplement websites reflect the same evidence as the trials?
Often no. Trial records and peer-reviewed papers are the best sources for the human evidence base. Marketing pages may overstate conclusions.
What should readers watch for in future fisetin clinical trial results?
The most useful future developments will be peer-reviewed outcomes from the ongoing healthy-aging, vascular-function, oncology, and PK/safety studies, especially if they clarify which schedule, population, and endpoint actually matter.
Schema recommendation
For most pages of this type, Article schema is justified because the content is primarily an editorial tracker with analysis and interpretation. Dataset schema is justified only if you maintain the trial table as a genuinely structured, updateable dataset with stable fields, clear versioning, and regular revisions. If the page remains mainly narrative with tables, Article schema alone is the cleaner choice.
Bottom line
If someone wants a realistic picture of fisetin clinical trials, the current answer is this: the human evidence base is expanding, but it is still early, mixed, and more notable for ongoing study activity than for definitive published results. A few important completed human studies exist, including one randomized trial with negative findings, a small mixed-result pilot study, and a couple of completed registry-result records without peer-reviewed papers yet. The ongoing pipeline is worth tracking closely, but it has not yet produced a universally persuasive clinical case for fisetin. ClinicalTrials.gov: NCT07195318 ClinicalTrials.gov: NCT06431932 ClinicalTrials.gov: NCT06133634 PubMed PMID 33802381 PubMed PMID 39269340
This article is intended for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making significant changes to your diet, exercise routine, or supplement regimen, especially if you have an existing medical condition, are pregnant or breastfeeding, or take prescription medications.